$IVBXF

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

Innovent Biologics (HKEX: 01801) expanded its Phase 3 MarsLight-11 trial of IBI363/TAK-928 to include non-squamous NSCLC patients. The trial, co-developed with Takeda, evaluates the drug's efficacy against docetaxel. IBI363/TAK-928 has received FDA and NMPA designations.

Analysts from SDIC Securities and CMB International Securities maintained Buy ratings on Sichuan Kelun-Biotech (HK:6990) with price targets of HK$571.39 and HK$642.29, respectively. Innovent Biologics (IVBXF) also received Buy ratings from CSC Financial and DBS, with price targets of HK$148.34 and HK$144.00, respectively. Both stocks have Strong Buy consensus ratings.

Innovent Biologics' stock rose 13% to a record high after reporting strong first-half 2026 results. Revenue increased 45% to RMB 8.6 billion, and net profit rose 50% to RMB 1.3 billion. The company aims for RMB 35-40 billion in revenue by 2030. Innovent led gains on the Hang Seng index, which rose 0.8%.

Innovent Biologics (IVBXF) reported 1H 2026 revenue of RMB 8.6B, up 45% YoY, with net profit rising 50%. The company aims to expand globally, targeting RMB 35-40B revenue by 2030, and has partnered with firms like Pfizer and Eli Lilly for over 20 assets.

Innovent Biologics (01801.HK) and Daiichi Sankyo (4568) signed an exclusive China commercialization agreement for Vanflyta (quizartinib). Daiichi will handle development, manufacturing and supply, while Innovent has sole commercialization and promotion rights in China. Vanflyta was approved in China in June 2026 for newly diagnosed FLT3-ITD positive AML, based on QuANTUM-First.

Innovent Biologics said it signed an exclusive licensing deal with Spero Therapeutics for IBI355, an anti-CD40L antibody for autoimmune diseases. Innovent will get an upfront payment plus development, regulatory and commercial milestones totaling up to about $1.1 billion, and tiered royalties. Spero gets worldwide rights excluding Greater China. IBI355 is in Phase 1 and Phase 2 plans.

Innovent Biologics (01801.HK) and Spero Therapeutics (SPRO) announced an exclusive global license for IBI355 (SP001), an anti-CD40L antibody, with Spero holding rights worldwide excluding Greater China. Innovent will receive an upfront payment and milestones totaling about $1.1B plus tiered royalties. Spero plans Phase 2 in IgG4-RD in Q2 2027 and Innovent Phase 2 in China for Sjögren’s by early 2027.

Innovent Biologics said updated Phase 1 PoC data for IBI363, a PD-1/IL-2a bispecific fusion protein, showed positive efficacy in immunotherapy-resistant advanced NSCLC. In 136 patients, including 67 squamous and 58 EGFR wild-type adenocarcinoma, median PFS/OS at 3 mg/kg Q3W were 10.1/18.2 months (24-month OS 47.8%) and 4.2/15.2 months (24-month OS 42.7%). Safety was manageable, according to the company. IBI363 is co-developed with Takeda.